Newsroom

September 2020

• Press release Sep 16, 2020

  Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond

  First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access…
• Featured News Sep 16, 2020

  Committed to increasing access

  Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

• Press release Sep 14, 2020

  European Medicines Agency (EMA) approves safety label update for Novartis Beovu®

  Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD   The update includes the additional characterization of retinal…
• 
  Story Sep 14, 2020 Discovery

  Bringing science and medicine together to help patients with cancer

  Alice Shaw, Global Head of Translational Clinical Oncology at Novartis, applies lessons from running clinical trials to the work of designing them.

• Press release Sep 14, 2020

  Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)

  In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1…
• In The News Sep 14, 2020

  Proactive scenario planning and supply risk management

  Steffen Lang, Global Head Novartis Technical Operations, on communication, data and automation during the COVID-19 crisis.
• Press release Sep 11, 2020

  Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

  Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the…
• Press release Sep 11, 2020

  Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

  New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated…
• 
  Story Sep 11, 2020 Discovery

  Not your grandparents’ nuclear medicine

  Novartis is taming nuclear power and putting it to use to treat advanced cancer.

• Featured News Sep 09, 2020

  New report shows how AI in health is critical for COVID-19 response and recovery

• Press release Sep 08, 2020

  Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

  Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for…
• 
  Story Sep 07, 2020 Patient Perspectives

  Reimagining asthma care: how data and digital could bring asthma management goals within reach

  Bertrand Bodson explains the Novartis strategy for digital innovation in asthma care.